Effects of combination treatment with dipeptidyl peptidase IV inhibitor and sulfonylurea on glucose levels in rats

Journal of Pharmacological Sciences

Volumn 95, Issue 2, 2004, Pages 291-293

  Takasaki, Kotaro ^a   Nakajima, Takao ^a   Ueno, Kimihisa ^a   Nomoto, Yuji ^a   Higo, Katsuya ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Dipeptidyl peptidase IV; Glibenclamide; Glucose tolerance

Indexed keywords

1 [4 METHYL 1 (2 PYRIMIDINYL) 4 PIPERIDYLAMINOACETYL] 2 PYRROLIDINECARBONITRILE; 1 [4 METHYL 1 (2 PYRIMIDINYL) 4 PIPERIDYLAMINO]ACETYL 2 PYRROLIDINECARBONITRILE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLUCOSE; SULFONYLUREA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POSTPRANDIAL STATE; RAT; TIME SERIES ANALYSIS;

EID: 3142517869     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.SC0040043     Document Type: Article

References (14)

1. Holst JJ. Enteroglucagon. Annu Rev Physiol. 1997;59:257-271.
2. Pauly RP, Demuth H-U, Rosche F, et al. Inhibition of dipeptidyl peptidase IV (DP IV) in rat results in improved glucose tolerance. Regul Pept. 1996;64:148.
3. Miyake H, Takimoto M, Hughes TE, Kimura M. Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: study using a Fischer 344 rat substrain deficient in its enzyme activity. Jpn J Pharmacol. 2002;88:442-450.
4. Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-Hydroxy-1-adamantyl) amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem. 2003;46:2774-2789.
5. Takasaki K, Iwase M, Nakajima T, et al. K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent. Eur J Pharmacol. 2004;486:335-342.
6. Asplund K, Wiholm BE, Lithner F. Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia. 1983;24:412-417.
7. Binder C, Bendtson I. Endocrine emergencies. Hypoglycaemia. Baillieres Clin Endocrinol Metab. 1992;6:23-39.
8. Stahl M, Berger W. Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabetic Med. 1999;16:586-590.
9. Matsumoto K, Sera Y, Abe Y, Tominaga T, Ueki, Miyake S. Combination therapy of alpha-glucosidase inhibitor and a sulfonylurea compound prolongs the duration of good glycemic control. Metabolism. 2002;51:1548-1552.
10. Marre M, Howlett H, Lehert P, Allavoine T. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin. Diabet Med. 2002;19:673-680.
11. Gutniak MK, Juntti-Berggren L, Hellstrom PM, Guenifi A, Holst JJ, Efendic S. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care. 1996;19:857-863.
12. Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide I in the anesthetized pig. Diabetes. 1998;47:764-769.
13. Kubota T, Flentke GR, Bachovchin WW, Strollar BD. Involvement of dipeptidyl peptidase IV in an in vivo immune response. Clin Exp Immunol. 1992;89:192-197.
14. Panteri U, Schwanstecher M, Schwanstecher C. Pancreatic and extrapancreatic sulfonylurea receptors. Horm Metab Res. 1992;24:549-554.